Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a group of diseases including emphysema (damage to the air sacs in the lungs) and chronic bronchitis (long-term inflammation of the airways). COPD is characterised by persistent respiratory symptoms and limitation in the airflow, which is due to airway abnormalities, alveolar abnormalities or both. This is usually caused by significant exposure to noxious particles, gases or air pollutants in the home and workplace, genetic factors, and respiratory infections can also be involved.
Symptoms of COPD include dyspnoea (shortness of breath or breathlessness), frequent coughing or wheezing and excess phlegm, mucus or sputum production. Patients with severe COPD may develop a number of extra pulmonary symptoms, such as fatigue, anorexia and weight loss which correlate with disease exacerbations due to bacterial and viral infections.
Whereas smoking cessation and increased physical activity can be used to treat the impact of COPD, bronchodilators and anti-inflammatory drugs therapy (whether used in combination or alone) are the main therapies available. Pulmonary rehabilitation and supplemental oxygen can also be beneficial.
To find out more about COPD visit our dedicated Learning Zone, which contains further information on treatment, medication and guidelines for this condition.
COPD Knowledge Centre
Within the COPD Knowledge Centre you will find details of upcoming events, highlights from recent conferences and useful resources. The site also provides an educational disease overview section, where guidelines can be viewed along with information on treatment and diagnosis. A new section dedicated to COPD in Women is now available and features a set of videos discussing COPD from the female perspective.
Freshly updated for 2017, the latest edition of the Global Strategy document is the premiere evidence-based reference tool for the implementation of effective disease management plans, and represents the current best practices...
Related news and insights
Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) demonstrated a statistically significant reduction in the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
AstraZeneca announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with...